Abstract
21 patients with growth retardation secondary to Growth Hormone deficiency have been studied prospectively during a control period of 6 months and 3 six-month therapy periods during which they received in random order Oxandrolone (Anavar ®) alone, .25mg/Kg/day; HGH alone, 2 IU-3x per week; or a combination of these two drugs in the doses mentioned. Careful height measurements and bone-age determinations were made at the beginning and end of each of the four study periods.
The patients studied included 10 with idiopathic panhypopituitarism (Group I), 6 with panhypopituitarism secondary to craniopharyngioma (Group II), and 5 with isolated growth hormone deficiency associated with other primary non-endocrine pathology. Patients with thyroid and/or adrenal insufficiency were maintained on appropriate substitution therapy throughout all four study periods.
Results indicate that in Groups I and II Oxandrolone was effective in stimulating growth, HGH was more effective, and the combination of the two drugs was even more effective. In Group III, none of the therapy regimens was significantly effective. In all groups and study periods advancement in bone age was quite similar to that in height age, thus providing no substantiation for concern over compromising eventual adult height attainment.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tattoni, D., Kelley, V. COMPARISON OF HUMAN GROWTH HORMONE (HGH) AND OXANDROLONE AS GROWTH STIHULATING AGENTS IH PATIENTS WITH GROWTH HORMONE DEFICIENCY. Pediatr Res 8, 375 (1974). https://doi.org/10.1203/00006450-197404000-00213
Issue Date:
DOI: https://doi.org/10.1203/00006450-197404000-00213